Clinical Trials Explained: How New Drugs Get Tested

By Newsroom, Health Desk — Published August 7, 2026

Table of Contents

• Clinical Trials Explained: The Four-Phase Journey
• The Science Behind Randomization and Control Groups
• Who Participates and Why Inclusion Matters
• From Lab to Pharmacy: The Regulatory Gauntlet
• The Economics and Ethics of Drug Development
• The Expanding Landscape: Telemedicine and Decentralized Trials
• Frequently Asked Questions

Every pill in your medicine cabinet, every vaccine administered by healthcare providers, every injection that improves patient outcomes began its journey in a clinical trial. These carefully orchestrated studies stand between a promising compound in a laboratory and a treatment you can actually receive. Understanding how clinical trials work matters because they shape everything from the medical treatment options available to you, to what health insurance coverage will pay for, to which pharmaceutical developments reach pharmacy shelves.

The process isn’t quick. A new drug typically spends a decade or more in development before it reaches patients. But that timeline exists for a reason: to determine whether a treatment actually works and whether it’s safe enough to use.

Clinical Trials Explained: The Four-Phase Journey

Clinical trials unfold in distinct phases, each designed to answer specific questions. Phase I trials are small, usually involving fewer than 100 participants, often healthy volunteers. Researchers aren’t primarily looking for effectiveness here. They want to know: Is this safe? What dose can the human body tolerate? How does the body process this compound?

Phase II expands the participant pool to several hundred people who actually have the condition the drug targets. Now effectiveness enters the picture. Does the treatment show promise? What side effects emerge? Researchers refine dosing and watch for red flags that might halt development entirely.

Phase III represents the major test. These trials can involve thousands of participants across multiple sites, sometimes in different countries. One group receives the experimental treatment; another gets either a placebo or the current standard treatment. Neither participants nor the healthcare providers administering the treatment know who receives what—a design called double-blind that prevents bias from creeping into results. These trials generate the data that regulatory agencies use to decide whether a drug can be marketed.

Phase IV happens after approval. Once a drug reaches the market, researchers continue monitoring it in the real world, watching for rare side effects that smaller trials might have missed and gathering data on long-term patient outcomes.

The Science Behind Randomization and Control Groups

The gold standard for clinical trials is the randomized controlled trial. Randomization means participants are assigned to treatment or control groups by chance, not by choice. This design prevents selection bias—the possibility that healthier or more motivated patients might cluster in one group, skewing results.

Control groups provide the comparison that makes results meaningful. If 60 percent of patients improve on a new drug, that sounds promising. But if 55 percent improve on a placebo, the drug’s real benefit shrinks considerably. The human body has remarkable healing capacity, and the placebo effect is genuine. Without a control group, there’s no way to separate a drug’s actual impact from what would have happened anyway.

Blinding takes this further. When neither participants nor researchers know who receives the experimental treatment, expectations can’t influence outcomes. A doctor who knows a patient is receiving a promising new therapy might unconsciously interpret ambiguous symptoms more favorably. A patient who believes they’re getting a powerful treatment might report feeling better regardless of the drug’s biological effect.

Who Participates and Why Inclusion Matters

Clinical trials depend on volunteers. Some join because standard medical treatment options have failed them. Others participate in disease prevention research while healthy, hoping to contribute to future breakthroughs. Some are motivated by access to cutting-edge care and close monitoring by healthcare providers. Others simply want to advance medical science.

Participation isn’t without burden. Trials often require frequent visits, extensive testing, and detailed symptom tracking. Some impose dietary restrictions or limit other medications. There’s always uncertainty—the experimental treatment might prove less effective than the standard, or it might cause unexpected side effects.

Historically, clinical trials have struggled with representation. Many studies oversampled white men, leading to drugs that might work differently in women, in various ethnic groups, or in older adults. A treatment optimized for a 45-year-old man might have different effects in a 70-year-old woman with multiple chronic conditions. Modern trial design increasingly emphasizes diverse recruitment, recognizing that medical research breakthroughs should benefit everyone, not just narrow demographic slices.

From Lab to Pharmacy: The Regulatory Gauntlet

Before a drug even reaches human trials, it undergoes years of laboratory and animal testing. Researchers identify a biological target—perhaps a protein that cancer cells need to multiply, or a receptor that influences blood pressure. They design molecules to interact with that target, then test thousands of variations to find the most promising candidates.

Animal studies come next, examining safety and biological activity in living organisms. Only after this extensive preclinical work can researchers apply to begin human trials. Regulatory agencies review the application, the preclinical data, and the proposed trial design before giving permission to proceed.

After Phase III trials conclude, the drug sponsor submits a comprehensive application containing sometimes hundreds of thousands of pages of data. Regulators scrutinize manufacturing processes, clinical results, proposed labeling, and safety monitoring plans. They may convene advisory committees of outside experts. They often request additional information or analyses. Approval can take months or years.

Even after approval, pharmaceutical developments face ongoing scrutiny. If serious safety issues emerge, regulators can require new warnings, restrict use, or pull drugs from the market entirely. Post-market surveillance through Phase IV trials and adverse event reporting systems continues throughout a drug’s lifetime.

The Economics and Ethics of Drug Development

Developing a new drug costs hundreds of millions to billions of dollars. Most experimental compounds fail. The successful drugs must generate enough revenue to cover not only their own development costs but also the expenses of the many failures. This economic reality shapes everything from which diseases attract research investment to how health insurance coverage decisions get made.

Rare diseases present particular challenges. A condition affecting a few thousand people worldwide offers a much smaller potential market than one affecting millions. Some policy mechanisms, like extended exclusivity periods for orphan drugs, attempt to incentivize development for small patient populations.

Ethical questions permeate clinical research. Is it acceptable to give some participants a placebo when an effective treatment already exists? How do researchers balance the need for rigorous data with the desire to help desperately ill patients access experimental therapies? When should a trial be stopped early because results are so positive—or so negative—that continuing would be unethical?

Informed consent represents the ethical cornerstone. Participants must understand the trial’s purpose, procedures, risks, and benefits before enrolling. They can withdraw at any time. Institutional review boards evaluate trial protocols to ensure they protect participant welfare and rights.

The Expanding Landscape: Telemedicine and Decentralized Trials

Traditional trials required participants to visit research centers repeatedly, sometimes traveling long distances. Telemedicine services are changing this model. Decentralized or hybrid trials use technology to bring some trial activities to participants’ homes. Wearable devices collect continuous data on heart rate, activity, and sleep. Video consultations replace some in-person visits. Local healthcare providers can perform certain procedures, sending results to the central research team.

This approach can improve access, particularly for people in rural areas or those with mobility limitations. It can enhance diversity by reducing the burden of participation. But it also introduces new challenges around data quality, device reliability, and ensuring adequate safety monitoring.

The COVID-19 pandemic accelerated adoption of these methods. Trials that might once have been considered impossible to conduct remotely proceeded with adapted protocols, demonstrating both the feasibility and the limitations of decentralized approaches.

Frequently Asked Questions

How long does it take for a new drug to go from initial research to pharmacy availability?

The journey typically takes 10 to 15 years from initial discovery through regulatory approval. Preclinical research might consume three to six years. The three phases of clinical trials usually require six to seven years combined, though timelines vary widely. Regulatory review adds another year or more. Some drugs move faster, particularly those addressing urgent unmet needs, while others take even longer if trials encounter setbacks or require additional studies.

Can I get paid for participating in a clinical trial?

Compensation varies by trial type and phase. Early-phase trials involving healthy volunteers often provide payment for time and inconvenience, sometimes substantial amounts for studies requiring overnight stays or intensive monitoring. Trials for specific diseases typically don’t pay participants directly, though they usually cover all treatment costs and may reimburse travel expenses. The ethical concern is ensuring payment doesn’t become so large that it unduly influences people to accept risks they otherwise wouldn’t.

What happens if I experience side effects during a trial?

Clinical trials include detailed safety monitoring. Participants receive clear instructions on reporting symptoms and typically have 24-hour access to the research team. If you experience concerning side effects, the team will evaluate whether you should continue in the trial. Treatment for trial-related side effects is provided at no cost. Serious adverse events trigger immediate review and may lead to pausing enrollment or modifying the protocol. Your safety takes precedence over trial completion.

How do researchers decide what diseases to study and what drugs to develop?

Multiple factors influence these decisions. Scientific opportunity matters—researchers pursue targets where biological understanding suggests intervention might work. Unmet medical need drives some research, particularly for conditions lacking effective treatments. Market size influences pharmaceutical company decisions, as larger patient populations offer greater revenue potential. Public health initiatives and government funding can direct research toward priority areas like disease prevention or chronic disease management. Academic researchers often focus on fundamental questions that might not have immediate commercial applications but advance overall scientific knowledge.

Clinical trials represent medicine’s essential quality control mechanism. They’re imperfect, sometimes slow, occasionally frustrating. But they’re also the reason modern healthcare providers can offer treatments that actually work, that wellness programs rest on evidence rather than guesswork, and that patient outcomes continue improving generation after generation. The next time you take a medication, someone, somewhere, volunteered to help determine it was safe and effective. That’s the human foundation beneath every pharmaceutical breakthrough.